Bruce MA, Stephen DH, Haehner-Daniels DB, Gorski JC. In vivo effect of
clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 2001;29:1023–
1028.
Cayen MN. Considerations in the design of toxicokinetic programs. Toxicol Pathol
1995a;23 (2):148–157.
Cayen MN. Toxicokinetic challenges in the pharmaceutical industry. Toxicol Pathol
1995;23 (2):217–219.
Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, Sewing KF.
Identification of drugs inhibiting thein vitrometabolism of tacrolimus by human
liver microsomes. Br J Clin Pharmacol 1996;41:187–190.
Dalvie D. Recent advances in the applications of radioisotopes in drug metabolism,
toxicology and pharmacokinetics. Curr Pharm Des 2000;6:1009–1028.
Davis-Bruno K and Atrakchi A. A regulatory perspective on issues and approaches in
characterizing human metabolites. Chem Res Toxicol 2006;19:1561–1563.
Desta Z, Soukhova N, Mahal SK, Flockhart DA. Interaction of cisapride with the
human cytochrome P450 system: metabolism and inhibition studies. Drug Metab
Dispos 2000;28:789–800.
FDA. Content and format of investigational new drug Applications (INDs) for phase 1
studies of drugs;1995.
FDA. Drug metabolism/drug interaction studies in the drug development process:
studiesin vitro;1997.
FDA.In Vivometabolism/drug interaction studiesstudy design, data analysis, and
recommendations for dosing and labeling;1999.
FDA. Bioanalytical method validation;2001a.
FDA. IND meetings for human drugs and biologics; chemistry, manufacturing, and
controls information;2001b.
FDA. Carcinogenicity study protocol submissions;2002.
FDA. CFR title 21, part 312––investigational new drug application;2003a.
FDA. CFR title 21, part 314––applications for FDA approval to market a new
drug;2003b.
FDA. Part 11, electronic records, electronic signatures––scope and application;2003c.
FDA. CFR title 21, part 58––good laboratory practice for nonclinical laboratory
studies;2003d.
FDA. CFR title 21, part 361.1––radioactive drugs for certain research uses;2005a.
FDA. Safety testing of drug metabolites (draft);2005b.
FDA. Drug interaction studies––study design, data analysis, and implications for
dosing and labeling (Draft guidance);2006a.
FDA. Labeling for human prescription drug and biological productsimplementing
the new content and format requirements (draft);2006b.
Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug
‘‘Pittsburgh cocktail’’ approach for assessment of selective regulation of drug-
metabolizing enzymes. Clin Pharmacol Ther 1997;62:365–376.
Greenblatt DJ, Wright CE, vonMoltke LL, Harmatz JS, Ehrenberg BL, Harrel LM,
Corbett K, Counihan M, Tobias S, Shader RI. Ketoconazole inhibition of triazolam
REFERENCES 233